The fibrinogen but not the Factor VIII content of transfused plasma determines its effectiveness at reducing bleeding in coagulopathic mice

Transfusion

Volumn 55, Issue 5, 2015, Pages 1040-1050

  Eltringham Smith, Louise J ^a   Lei, Xi ^b,c   Reheman, Adili ^c   Lambourne, Melissa D ^b   Pryzdial, Edward L ^b,d   Ni, Heyu ^b,c   Sheffield, William P ^a,b  

^a MCMASTER UNIVERSITY   (Canada)

^b CANADIAN BLOOD SERVICES   (Canada)

^c ST MICHAEL'S HOSPITAL   (Canada)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 8; FIBRINOGEN; FRESH FROZEN PLASMA; HUMAN ALBUMIN; PLASMA PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTERIOLE; ARTERY INJURY; ARTICLE; BLEEDING; BLEEDING TIME; BLOOD CLOTTING; BLOOD CLOTTING DISORDER; BLOOD STORAGE; BLOOD TRANSFUSION; CONTROLLED STUDY; ERYTHROCYTE; FEMALE; MALE; MICROSCOPY; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; PLASMA TRANSFUSION; QUANTITATIVE ANALYSIS; TAIL VEIN; THROMBOCYTE; WILD TYPE; ANIMAL; HEMOLYSIS; HEMORRHAGE; KNOCKOUT MOUSE; METABOLISM; PLASMAPHERESIS; PROCEDURES;

ANIMALS; ERYTHROCYTES; FACTOR VIII; FEMALE; FIBRINOGEN; HEMOLYSIS; HEMORRHAGE; MALE; MICE; MICE, KNOCKOUT; PLASMA EXCHANGE;

EID: 84929208576     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/trf.12931     Document Type: Article

References (51)

1. Stanworth SJ, Walsh TS, Prescott RJ, et al. A national study of plasma use in critical care: clinical indications, dose and effect on prothrombin time. Crit Care 2011;15:R108.
2. Canadian Blood Services. Circular of information. Toronto (ON): Canadian Blood Services, 2011.
3. Heemskerk JW, Mattheij NJ, Cosemans JM,. Platelet-based coagulation: different populations, different functions. J Thromb Haemost 2013;11:2-16.
4. Whelihan MF, Mann KG,. The role of the red cell membrane in thrombin generation. Thromb Res 2013;131:377-382.
5. Callum JL, Rizoli S,. Plasma transfusion for patients with severe hemorrhage: what is the evidence? Transfusion 2012;52(Suppl 1):30S-37S.
6. Tinmouth A,. Evidence for a rationale use of frozen plasma for the treatment and prevention of bleeding. Transfus Apher Sci 2012;46:293-298.
7. Stanworth SJ, Brunskill SJ, Hyde CJ, et al. Is fresh frozen plasma clinically effective? A systematic review of randomized controlled trials. Br J Haematol 2004;126:139-152.
8. Yang L, Stanworth S, Hopewell S, et al. Is fresh-frozen plasma clinically effective? An update of a systematic review of randomized controlled trials. Transfusion 2012;52:1673-1686; quiz.
9. Rock GA, Shumak KH, Buskard NA, et al. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group. N Engl J Med 1991;325:393-397.
10. Tinmouth A, Thompson T, Arnold DM, et al. Utilization of frozen plasma in Ontario: a provincewide audit reveals a high rate of inappropriate transfusions. Transfusion 2013;53:2222-2229.
11. Miller TE,. New evidence in trauma resuscitation-is 1:1:1 the answer? Perioper Med (Lond) 2013;2:13.
12. O'Shaughnessy DF, Atterbury C, Bolton Maggs P, Murphy M, Thomas D, Yates S, Williamson LM,. Guidelines for the use of fresh-frozen plasma, cryoprecipitate and cryosupernatant. Br J Haematol 2004;126:11-28.
13. Expert Working Group. Guidelines for red blood cell and plasma transfusion for adults and children. Can Med Assoc J 1997;156:S1-S24.
14. Transfusion Task Force. Amendments and corrections to the 'Transfusion Guidelines for neonates and older children' (BCSH, 2004a); and to the 'Guidelines for the use of fresh frozen plasma, cryoprecipitate and cryosupernatant' (BCSH, 2004b). Br J Haematol 2007;136:514-516.
15. UK Blood Transfusion Services. Guidelines for the blood transfusion services in the United Kingdom. London: The Stationery Office; 2005.
16. Grafstein E, Innes G,. Guidelines for red blood cell and plasma transfusion for adults and children: an emergency physician's overview of the 1997 Canadian Blood Transfusion Guidelines. Part 2: Plasma transfusion and infectious risk. J Emerg Med 1998;16:239-241.
17. Council of Europe. Guide to the preparation, use and quality assurance of blood components. Strasbourg: Council of Europe; 2007.
18. DiMichele D, Neufeld EJ,. Hemophilia. A new approach to an old disease. Hematol Oncol Clin North Am 1998;12:1315-1344.
19. Wyshock EG, Suffredini AF, Parrillo JE, et al. Cofactors V and VIII after endotoxin administration to human volunteers. Thromb Res 1995;80:377-389.
20. Sheffield WP, Bhakta V, Talbot K, et al. Quality of frozen transfusable plasma prepared from whole blood donations in Canada: an update. Transfus Apher Sci 2013;49:440-446.
21. Cardigan R, Lawrie AS, Mackie IJ, et al. The quality of fresh-frozen plasma produced from whole blood stored at 4 degrees C overnight. Transfusion 2005;45:1342-1348.
22. Zimring JC, Spitalnik SL,. On the appropriate use and interpretation of animal models in transfusion medicine research. Transfusion 2013;53:2334-2339.
23. Frith D, Cohen MJ, Brohi K,. Animal models of trauma-induced coagulopathy. Thromb Res 2012;129:551-556.
24. Letourneau PA, McManus M, Sowards K, et al. Aged plasma transfusion increases mortality in a rat model of uncontrolled hemorrhage. J Trauma 2011;71:1115-1119.
25. Dickneite G,. Prothrombin complex concentrate versus recombinant factor VIIa for reversal of coumarin anticoagulation. Thromb Res 2007;119:643-651.
26. Illanes S, Zhou W, Schwarting S, et al. Comparative effectiveness of hemostatic therapy in experimental warfarin-associated intracerebral hemorrhage. Stroke 2011;42:191-195.
27. Schlunk F, Van Cott EM, Hayakawa K, et al. Recombinant activated coagulation factor VII and prothrombin complex concentrates are equally effective in reducing hematoma volume in experimental warfarin-associated intracerebral hemorrhage. Stroke 2012;43:246-249.
28. Zhou W, Schwarting S, Illanes S, et al. Hemostatic therapy in experimental intracerebral hemorrhage associated with the direct thrombin inhibitor dabigatran. Stroke 2011;42:3594-3599.
29. Lambourne MD, Eltringham-Smith LJ, Gataiance S, et al. Prothrombin complex concentrates reduce blood loss in murine coagulopathy induced by warfarin, but not in that induced by dabigatran etexilate. J Thromb Haemost 2012;10:1830-1840.
30. Bi L, Lawler AM, Antonarakis SE, et al. Targeted disruption of the mouse factor VIII gene produces a model of haemophilia A. Nat Genet 1995;10:119-121.
31. Suh TT, Holmback K, Jensen NJ, et al. Resolution of spontaneous bleeding events but failure of pregnancy in fibrinogen-deficient mice. Genes Dev 1995;9:2020-2033.
32. Ni H, Denis CV, Subbarao S, et al. Persistence of platelet thrombus formation in arterioles of mice lacking both von Willebrand factor and fibrinogen. J Clin Invest 2000;106:385-392.
33. Reheman A, Gross P, Yang H, et al. Vitronectin stabilizes thrombi and vessel occlusion but plays a dual role in platelet aggregation. J Thromb Haemost 2005;3:875-883.
34. Reheman A, Yang H, Zhu G, et al. Plasma fibronectin depletion enhances platelet aggregation and thrombus formation in mice lacking fibrinogen and von Willebrand factor. Blood 2009;113:1809-1817.
35. Lei X, Reheman A, Hou Y, et al. Anfibatide, a novel GPIb complex antagonist, inhibits platelet adhesion and thrombus formation in vitro and in vivo in murine models of thrombosis. Thromb Haemost 2014;111:279-289.
36. Machlus KR, Cardenas JC, Church FC, et al. Causal relationship between hyperfibrinogenemia, thrombosis, and resistance to thrombolysis in mice. Blood 2011;117:4953-4963.
37. Sandrin MS, Vaughan HA, Dabkowski PL, et al. Anti-pig IgM antibodies in human serum react predominantly with Gal(alpha 1-3)Gal epitopes. Proc Natl Acad Sci U S A 1993;90:11391-11395.
38. Good AH, Cooper DK, Malcolm AJ, et al. Identification of carbohydrate structures that bind human antiporcine antibodies: implications for discordant xenografting in humans. Transplant Proc 1992;24:559-562.
39. Ansari S, Szallasi A,. Blood management by transfusion triggers: when less is more. Blood Transfus 2012;10:28-33.
40. Carless PA, Henry DA, Carson JL, et al. Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion. Cochrane Database Syst Rev 2010;(10): CD002042.
41. Morowski M, Vogtle T, Kraft P, et al. Only severe thrombocytopenia results in bleeding and defective thrombus formation in mice. Blood 2013;121:4938-4947.
42. Harkness JE, Wagner JE,. The biology and medicine of rabbits and rodents. In:, Harkness JE, Wagner JE, editors. Biology and husbandry. Philadelphia: Lea and Febiger; 1989. p. 372.
43. Burns ER, Goldberg SN, Wenz B,. Paradoxic effect of multiple mild coagulation factor deficiencies on the prothrombin time and activated partial thromboplastin time. Am J Clin Pathol 1993;100:94-98.
44. Desborough MJ, Stanworth SJ, Curry NS,. Uses and abuses of fresh frozen plasma for the treatment of bleeding. Clin Med 2013;13:200-202.
45. Desborough MJ, Stanworth SJ,. Uses and abuses of fresh-frozen plasma for the prophylaxis of bleeding. Clin Med 2013;13:197-199.
46. Abdel-Wahab OI, Healy B, Dzik WH,. Effect of fresh-frozen plasma transfusion on prothrombin time and bleeding in patients with mild coagulation abnormalities. Transfusion 2006;46:1279-1285.
47. Mosesson MW, Cooley BC, Hernandez I, et al. Thrombosis risk modification in transgenic mice containing the human fibrinogen thrombin-binding gamma' chain sequence. J Thromb Haemost 2009;7:102-110.
48. Krohn KA, DeNardo SJ, Wheeler DW, et al. I-fibrinogen as an oncophilic radiodiagnostic agent: distribution kinetics in tumour-bearing mice. Br J Cancer 1977;36:227-234.
49. Scott E, Puca K, Heraly J, et al. Evaluation and comparison of coagulation factor activity in fresh-frozen plasma and 24-hour plasma at thaw and after 120 hours of 1 to 6 degrees C storage. Transfusion 2009;49:1584-1591.
50. Sheffield WP, Bhakta V, Mastronardi C, et al. Changes in coagulation factor activity and content of di(2-ethylhexyl)phthalate in frozen plasma units during refrigerated storage for up to five days after thawing. Transfusion 2012;52:493-502.
51. Joziasse DH, Oriol R,. Xenotransplantation: the importance of the Galalpha1,3Gal epitope in hyperacute vascular rejection. Biochim Biophys Acta 1999;1455:403-418.